广泛的研究关注了癌症中单个 miRNA 的错调。最近，miRNA 的生物合成和加工机制的突变被认为与几种恶性肿瘤有关。这些突变可能导致全局 miRNA 错调，从而可能促进许多癌症的众所周知的特征。有趣的是，最近的证据也表明，致癌性 KRAS 突变在一定程度上通过调节 miRNA 调节通路中的成员的活动来发挥作用。在这里，我们强调了 miRNA 核心机制中的突变在促进恶性转化中的至关重要作用。此外，我们讨论了突变 KRAS 如何同时影响多个 miRNA 处理和功能步骤以促进肿瘤发生。虽然 KRAS 利用 miRNA 调节通路的能力增加了其致癌性的复杂性，但它也提供了一个尚未在临床上开发的潜在治疗途径。此外，同时针对突变 KRAS 和 miRNA 核心机制成员是治疗癌症的潜在策略。

Extensive studies have focused on the misregulation of individual miRNAs in cancer. More recently, mutations in the miRNA biogenesis and processing machinery have been implicated in several malignancies. Such mutations can lead to global miRNA misregulation, which may promote many of the well-known hallmarks of cancer. Interestingly, recent evidence also suggests that oncogenic KRAS mutations act in part by modulating the activity of members of the miRNA regulatory pathway. Here, we highlight the vital role mutations in the miRNA core machinery play in promoting malignant transformation. Furthermore, we discuss how mutant KRAS can simultaneously impact multiple steps of miRNA processing and function to promote tumorigenesis. Although the ability of KRAS to hijack the miRNA regulatory pathway adds a layer of complexity to its oncogenic nature, it also provides a potential therapeutic avenue that has yet to be exploited in the clinic. Moreover, concurrent targeting of mutant KRAS and members of the miRNA core machinery represents a potential strategy for treating cancer.